

# Flamigel®

## Hydroactive colloid gel with the power of arginine




### Flamigel® for the prevention<sup>1</sup> and treatment<sup>2</sup> of Radiotherapy-induced Skin Reactions

95% of all cancer patients treated with radiotherapy<sup>1</sup> experience skin reactions. Flamigel® is clinically proven to:


- Reduce moist desquamation<sup>1</sup>
- Restore the moisture balance of the skin
- Soothe pain<sup>2</sup>
- Reduce inflammation

**Non-Cytotoxic**

Flamigel® reduces the incidence of moist desquamation by 80% when used from the start of radiotherapy.<sup>1</sup>



Flamigel® prevents the onset of moist desquamation in 93% of patients when used from the start of radiotherapy.<sup>1</sup>



The preventive or the curative use of a colloidal hydroactive gel Flamigel® during radiotherapy, in comparison with the use of dexpanthenol significantly reduces the risk of radiation-induced moist desquamation.

Always read the label. Follow the directions for use. If symptoms persist consult your health professional.

**For further information or to receive a sample, call 1300 9 ARROW (27769)**

**References:** 1. Censabella et al., Hydroactive colloid gel vs historical controls for the prevention of radiotherapy-induced moist desquamation in breast cancer patients: Preliminary results *Annals of Oncology* (2016) 27 (6): 497-521. 10.1093/annonc/mdw390. 2. Censabella et al., Management of radiotherapy-induced skin reactions: Retrospective comparison of a hydroactive colloid gel and a dexpanthenol cream on the development of moist desquamation in breast cancer patients. *Eur J O N* 18 (2014) 499-504